News - Brenus Pharma

19 January 2023

“Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund

Paul Bravetti (Brenus CEO) & Jan Lichtenberg (InShpero CEO) interview about the collaborative project ALLOGENIX granted by the European Comission supporting the development of a companion test for the next-generation cancer cell immunotherapy STC-1010.

“Brenus Pharma designs a shield against resistant cancer cells”

To pursue R&D and finalize preclinical studies of the first candidate targeting metastatic colorectal cancer, Brenus Pharma has just completed a seed round of €4 million seed round involving: Jacques Gardette's familly office of Jacques Gardette, Biojag ; Bpifrance and the Caisse d'épargne Auvergne Limousin.

16 February 2022

“An anti-cancer shield created for each patient”

Brenus Pharma Story telling & closing of first financing round (€4M) & Added value of Brenus therapy compared to other treatments.

29 November 2022

Poster presentation during SITC annual meeting 2022

[CAM MODEL - STC1010 Efficacy prediction & MoA Validation]

29 November 2022

Poster presentation during SITC annual meeting 2022

[POC4 - Efficacy results of murine STC1010 in combination with SOC]

29 November 2022

Poster presentation during AACR annual meeting 2022

[POC3 - Efficacy results of murine STC1010 on a anti-PD1 resistant model]

1